Podcasts about clinical decision making

In this conversation, Dr. Jennie Berkovich and Dr. Alan Rozanski explore the intricate relationship between stress, optimism, and cardiac health. They discuss the impact of chronic stress on cardiovascular disease, the importance of resilience, and how positive mindsets can promote longevity. The dialogue emphasizes the need for a holistic approach to health that includes behavioral management, mindfulness, and exercise. Dr. Rozanski shares insights on how to effectively communicate these concepts to patients, highlighting the significance of time management in maintaining health. The conversation concludes with a look towards the future of cardiology and patient education.Dr. Alan Rozanski is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Chief Academic Officer, Executive Director of Cardiac Education and Fellowship Training Programs, and Director of Nuclear Cardiology for the Department of Cardiology at Mount Sinai St. Lukes.A graduate of Yale University and the Tufts University School of Medicine, Dr. Rozanski completed his Internal Medicine and Cardiology Fellowship training at Mount Sinai Hospital and a fellowship in Nuclear Medicine at Cedars-Sinai Medical Center in Los Angeles.While at Cedars-Sinai Medical Center, Dr. Rozanski founded a large multi-disciplinary program in Preventive and Rehabilitative Cardiology and initiated research which helped lead to the creation of a new field of Behavioral Cardiology. This led to a prestigious Sabbatical Fellowship from the MacArthur Foundation to study the determinants of health-promoting and health-damaging behaviors alongside many leading behavioral clinicians across the nation.In 1990, Dr. Rozanski joined the cardiology staff of St. Lukes/Roosevelt Hospital (now Mount Sinai St. Lukes and Mount Sinai West Hospitals) where he eventually served as Chief of Cardiology before assuming his current positions.Dr. Rozanski is noted for his unique clinical and academic focus and novel research that uniquely integrates the fields of Preventive Cardiology with Health Psychology and Behavioral Medicine.In addition, Dr. Rozanski is a leading expert in applying Cardiac Imaging for optimal Risk Assessment and Clinical Decision Making among patients who are candidates for cardiac testing due to risk factors or symptoms which are suggesting of heart disease.Dr. Rozanski is the co-author of over 270 peer-reviewed medical articles, book chapters and medical editorials, many of which are considered seminal contributions to the fields of Cardiology and/or Health Psychology._________________________________________________Sponsor the JOWMA Podcast! Email digitalcontent@jowma.orgBecome a JOWMA Member! www.jowma.orgFollow us on Instagram! www.instagram.com/JOWMA_orgFollow us on Twitter!www.twitter.com/JOWMA_medFollow us on Facebook! https://www.facebook.com/JOWMAorgStay up-to-date with JOWMA news! Sign up for the JOWMA newsletter! https://jowma.us6.list-manage.com/subscribe?u=9b4e9beb287874f9dc7f80289&id=ea3ef44644&mc_cid=dfb442d2a7&mc_eid=e9eee6e41e

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VPA865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until April 26, 2026.Illuminating a Better Path Forward for HR+, HER2- MBC: Bridging the Science and Art of Medicine in Clinical Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Breastcancer.org. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VPA865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until April 26, 2026.Illuminating a Better Path Forward for HR+, HER2- MBC: Bridging the Science and Art of Medicine in Clinical Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Breastcancer.org. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VPA865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until April 26, 2026.Illuminating a Better Path Forward for HR+, HER2- MBC: Bridging the Science and Art of Medicine in Clinical Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Breastcancer.org. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/EBAC/NCPD/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/VPA865. CME/EBAC/NCPD/AAPA/IPCE credit will be available until April 26, 2026.Illuminating a Better Path Forward for HR+, HER2- MBC: Bridging the Science and Art of Medicine in Clinical Decision-Making In support of improving patient care, this activity has been planned and implemented by PVI, PeerView Institute for Medical Education, and Breastcancer.org. PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure information is available at the beginning of the video presentation.

On this episode of the Sports Medicine Primer Series, host Dr. Zainab Shirazi, MD, continues the conversation with Dr. Dan Cushman, MD, discussing the management of a case of shoulder pain in a 23-year-old backpacker. The goal of this ongoing series is to be an audible study aid for anyone pursuing a career as a sports medicine physician and to prepare them for a sports medicine fellowship. Dr. Cushman is board-certified in both Sports Medicine and Physical Medicine & Rehabilitation, and specializes in the care of musculoskeletal injuries in both athletes & non-athletes, musculoskeletal ultrasound, electrodiagnostics, and endurance sports-specific injuries. He serves as the team physician for the University of Utah Track & Field and Cross-Country teams and is also the team physician for the University of Utah Swimming and Diving teams. Dr. Shirazi is a Sports Medicine Fellow at the University of Colorado. She completed her residency training in Physical Medicine & Rehabilitation (PM&R) at NewYork-Presbyterian Columbia/Cornell, where she served as Chief Resident, and is the current Fellow Chair for AMSSM's Library of Ultrasound Pathology. She is passionate about women's sports medicine and providing specialized care for female athletes. Resources: Best Practices in Sports Medicine: AMSSM and AOASM Case Studies (1st ed) – Case 66 (p. 395): https://amssmstore.com/best-practices-in-sports-medicine-amssm-and-aoasm-case-studies Peripheral Neuropathies of the Upper Extremity | National Fellow Online Lecture Series: https://www.youtube.com/watch?v=vC0XgHvQWXc Unilateral Winged Scapula: Clinical and Electrodiagnostic Experience with 128 cases, With Special Attention to Long Thoracic Nerve Palsy: https://onlinelibrary.wiley.com/doi/full/10.1002/mus.26059 The Natural History of Long Thoracic and Spinal Accessory Neuropathies: https://onlinelibrary.wiley.com/doi/full/10.1002/mus.10068 MR Neurography (MRN) of the Long Thoracic Nerve: Retrospective Review of Clinical Findings and Imaging Results at Our Institution Over 4 Years: https://link.springer.com/article/10.1007/s00256-017-2737-z Ortho Bullets – Scapular Winging: https://www.orthobullets.com/shoulder-and-elbow/3062/scapular-winging Surgical and Clinical Decision Making in Isolated Long Thoracic Nerve Palsy: https://journals.sagepub.com/doi/full/10.1177/1558944717733306 A Comprehensive Analysis of Pectoralis Major Transfer for Long Thoracic Nerve Palsy: https://www.sciencedirect.com/science/article/pii/S1058274614006818

On this episode of the Sports Medicine Primer Series, host Dr. Zainab Shirazi, MD, is joined by Dr. Dan Cushman, MD, to discuss how to manage a case of shoulder pain in a 23-year-old backpacker. The goal of this ongoing series is to be an audible study aid for anyone pursuing a career as a sports medicine physician and to prepare them for a sports medicine fellowship. Dr. Cushman is board-certified in both Sports Medicine and Physical Medicine & Rehabilitation, and specializes in the care of musculoskeletal injuries in both athletes & non-athletes, musculoskeletal ultrasound, electrodiagnostics, and endurance sports-specific injuries. He serves as the team physician for the University of Utah Track & Field and Cross-Country teams and is also the team physician for the University of Utah Swimming and Diving teams. Dr. Shirazi is a Sports Medicine Fellow at the University of Colorado. She completed her residency training in Physical Medicine & Rehabilitation (PM&R) at NewYork-Presbyterian Columbia/Cornell, where she served as Chief Resident, and is the current Fellow Chair for AMSSM's Library of Ultrasound Pathology. She is passionate about women's sports medicine and providing specialized care for female athletes. Resources: Best Practices in Sports Medicine: AMSSM and AOASM Case Studies (1st ed) – Case 66 (p. 395): https://amssmstore.com/best-practices-in-sports-medicine-amssm-and-aoasm-case-studies Peripheral Neuropathies of the Upper Extremity | National Fellow Online Lecture Series: https://www.youtube.com/watch?v=vC0XgHvQWXc Unilateral Winged Scapula: Clinical and Electrodiagnostic Experience with 128 cases, With Special Attention to Long Thoracic Nerve Palsy: https://onlinelibrary.wiley.com/doi/full/10.1002/mus.26059 The Natural History of Long Thoracic and Spinal Accessory Neuropathies: https://onlinelibrary.wiley.com/doi/full/10.1002/mus.10068 MR Neurography (MRN) of the Long Thoracic Nerve: Retrospective Review of Clinical Findings and Imaging Results at Our Institution Over 4 Years: https://link.springer.com/article/10.1007/s00256-017-2737-z Ortho Bullets – Scapular Winging: https://www.orthobullets.com/shoulder-and-elbow/3062/scapular-winging Surgical and Clinical Decision Making in Isolated Long Thoracic Nerve Palsy: https://journals.sagepub.com/doi/full/10.1177/1558944717733306 A Comprehensive Analysis of Pectoralis Major Transfer for Long Thoracic Nerve Palsy: https://www.sciencedirect.com/science/article/pii/S1058274614006818

TakeawaysMetatarsal stress fractures are common injuries in athletes.Understanding the remodeling process of bones is crucial for recovery.Subjective questioning can reveal important clues about the injury.Palpation techniques are essential for accurate diagnosis.Systemic factors like energy availability can influence bone health.Imaging, particularly MRI, is vital for diagnosing bone stress injuries.Treatment should focus on offloading the affected area.Recovery time varies significantly between individuals and injuries.Communication with patients about their condition is key to effective treatment.Injury prevention strategies should include monitoring training loads. ** You should always see a medical professional for diagnoses and assessment. This is not medical advice and is for educational purposes only.SummaryIn this episode of the Sports Medicine Project, hosts Blake and Kelly delve into the complexities of diagnosing metatarsal stress fractures and bone stress injuries. They discuss the importance of understanding the clinical assessment process, including subjective questioning, palpation techniques, and the role of imaging in diagnosis. The conversation emphasizes the significance of systemic factors and adequate recovery in preventing these injuries, as well as the need for effective treatment strategies. The hosts share insights from their clinical experiences, making the discussion both informative and engaging for listeners interested in sports medicine and injury management.Chapters00:00 Introduction and Overview of Metatarsal Injuries03:01 Understanding Bone Stress Injuries05:46 Diagnosis and Clinical Assessment09:04 The Role of Training Load and Recovery12:06 Systemic Factors Influencing Bone Health14:49 Imaging and Diagnostics for Metatarsal Injuries18:01 Palpation Techniques and Patient History20:53 Conclusion and Key Takeaways25:35 Palpation Techniques for Metatarsal Assessment32:06 Clinical Decision-Making in Bone Stress Injuries37:54 Differentiating Between Tendon and Bone Injuries48:02 Imaging and Diagnosis of Bone Stress InjuriesKeywordsmetatarsal stress fracture, bone stress injury, diagnosis, clinical assessment, imaging, treatment, sports medicine, recovery, palpation techniques, systemic factors

Gregs social: https://www.instagram.com/greglehman/Pro version Heidi AI Scribe (time saver) Link: ⁠https://scribe.heidihealth.com/?via=SMP⁠Support the show: ⁠https://patreon.com/SportsMedicineProject?utm_medium=unknown&utm_source=join_link&utm_campaign=creatorshare_creator&utm_content=copyLinkGregs Website: https://www.greglehman.ca/Chapters00:00 Evaluating Shockwave Therapy in Tendinopathy00:44 The Role of Exercise in Rehabilitation03:43 Understanding Patient Ecosystems and Health06:23 Case Studies: Practical Applications in Treatment08:49 The Complexity of Pain Management11:43 Research Critique: Shockwave Therapy and Evidence14:10 Psychological Factors in Pain Perception17:02 Clinical Decision-Making in Patient Care26:00 Trusting Experts and Knowledge Translation27:21 Challenging Established Beliefs28:30 Comparing Treatment Philosophies31:03 The Role of Patient Understanding33:35 Exercise vs. Alternative Treatments34:26 Load Management in Rehabilitation35:54 Creative Approaches to Running Rehabilitation37:06 Resistance Training for Runners40:12 Skepticism Towards New Research42:50 Understanding Bone Stress Injuries54:53 Understanding Pain and Structural Changes58:59 Navigating Risks in Running Injuries01:04:20 The Role of Social Media in Health Information01:09:39 Strength Training and Recovery Insights01:12:24 Research Aspirations and Future DirectionsKeywords:shockwave therapy, tendon rehabilitation, exercise, pain management, sports medicine, patient education, metabolic health, case studies, research appraisal, individualized treatment, training protocols, bone health, stress fractures, plyometric training, rehabilitation, pain management, social media, health information, research ethics, performance.Summary:This conversation delves into the complexities of sports medicine, focusing on shockwave therapy, exercise rehabilitation, and the importance of understanding patient ecosystems. The speakers discuss recent research findings, the role of exercise in pain management, and the need for individualized treatment approaches. They also explore the psychological factors influencing pain and the critical appraisal of existing research in the field. In this conversation, Blake Withers and Greg delve into various aspects of training protocols, bone health, and the complexities of rehabilitation. They discuss the importance of flexibility in training, the role of frequency in plyometric exercises, and the nuances of managing pain in relation to structural changes. The dialogue also touches on the ethical considerations of pain in research, the impact of social media on health information, and future directions in rehabilitation research.takeawaysShockwave therapy may not provide additional benefits compared to exercise.Exercise should be critically evaluated just like other treatments.Improving a patient's overall health ecosystem is challenging but essential.Patient motivation is crucial for successful rehabilitation.Understanding the mechanisms of pain can enhance treatment outcomes.Research in sports medicine often lacks strong evidence for certain treatments.Individualized treatment plans are necessary for effective rehabilitation.Psychological factors play a significant role in pain perception.Exercise can positively influence peripheral nociception.Critical appraisal of research is vital for informed clinical practice. People can improve despite not following traditional protocols.Flexibility in training is crucial for optimal results.Frequency of training may be more important than intensity.Understanding bone health is essential for preventing stress fractures.Pain is not always a reliable indicator of injury severity.Social media can be a double-edged sword for health information.Research ethics play a significant role in studying pain management.The relationship between structure and pain is complex and often misunderstood.

Sarah Spaulding joins Ethics Talk to discuss her article, coauthored Dr Katherine Fischkoff: “How Should We Understand Regret as a Moral Psychological Experience That Can Influence Clinical Decision-Making?”  Recorded January 9, 2024.  Read the article for free at JournalOfEthics.org

Dr. E is joined by his new co-host and good friend, Dr. Sean Wells, from Nutritional Physical Therapy. They talk about two ankle cases, both injuries. Dr. E discovered an old classic reset helped both cases WB with significantly less pain. Then they discuss this article by Dr. Tom Michaud, DC and how it has impacted their practice and Clinical Decision Making.Untold Physio Stories is sponsored by⁠Comprehend PT⁠- Leave Comprehend PT running in the background or record audio when you have time. The AI based SOAP note generator does the rest! No need for accuracy or exact wording! It's a game changer and will give you more time with your patients! Use code MMT50 to save 50% off your first month. Free trial available at sign up!⁠⁠The Eclectic Approach Network⁠⁠ - Check out Dr. E's all new private, non tracking and ad free network for rehab pros! It's free to join, has chat, feed, and all the features of other social networks without the creeping tracking.Check out ⁠⁠EDGE Mobility System⁠⁠'s Best Sellers - Something for every PT, OT, DC, MT, ATC or Fitness Minded Individual https://edgemobilitysystem.com

Could the key to more effective allergy therapies lie in the nasal microbiome? In this episode of BackTable ENT, Dr. Jennifer Villwock from Kansas University Medical Center discusses the intricacies of treating allergies and sinus issues with hosts Dr. Ashley Agan and Dr. Gopi Shah. --- SYNPOSIS Dr. Villwock begins by highlighting the importance of personalized medicine and the role of the microbiome in immunotherapy. Topics include topical and oral probiotics, the nasal microbiome, intralymphatic immunotherapy, and the significance of accurate allergy testing. Dr. Villwock also shares insights on sublingual and subcutaneous immunotherapy, the future of allergy treatments, and the impact of environmental factors on sinus health. --- TIMESTAMPS 00:00 - Introduction 01:53 - Understanding the Sinus Microbiome 04:34 - The Role of the Microbiome in Health 09:31 - Challenges in Microbiome Research 23:21 - Clinical Decision-Making in Antibiotic Use 25:07 - Exploring Probiotics & Dietary Factors for Sinus Health 30:12 - Immunotherapy and Microbiome 35:47 - Allergy Testing Methods 41:40 - Future Directions in Immunotherapy 44:18 - Conclusion and Final Thoughts --- RESOURCES Jennifer Villwock Profile https://www.kumc.edu/jvillwock.html AAOA 2025 Explorers Course in Allergy and Immunology, Vail, CO. March 27-29, 2025 https://www.aaoallergy.org/education/aaoa-explorers-course-2025/ BackTable+ for ENT https://plus.backtable.com/pages/ent Check out BackTable+ for ENT, our sponsor and new e-learning platform! https://plus.backtable.com/pages/ent

Read the article here: https://journals.sagepub.com/doi/full/10.1177/30494826241296412

In this episode of the PFC podcast, Dr. Jim DeCanto, an experienced anesthesiologist, discusses the critical aspects of airway management in emergency situations. He emphasizes the importance of decision-making processes, assessing neurological status, and the necessity of proper planning and preparation for airway interventions. The conversation highlights the challenges faced in both hospital and pre-hospital settings, the significance of having the right equipment, and the need for practitioners to be confident in their skills. Dr. DeCanto shares valuable insights and advice for new practitioners in the field, stressing the importance of thorough assessments and timely interventions to ensure patient safety. Takeaways Airway management is a critical skill for anesthesiologists. Decision-making in emergencies can be complex and requires a plan. Assessing neurological status is crucial before airway interventions. Proper planning and preparation can enhance confidence in emergency situations. Communication with patients, even when unconscious, is important. Practitioners must be ready to act when necessary, as no one else may be available. Understanding the tools and techniques for airway management is essential. Experience and continuous learning are key to improving skills in airway management. Practitioners should not hesitate to perform necessary procedures when indicated. Physical exams and clinical judgment are vital in emergency medicine. Chapters 00:00 Introduction to Airway Management 03:05 Decision-Making in Emergency Situations 12:29 Assessing Neurological Status 20:40 Planning and Preparing for Airway Management 30:50 Clinical Decision-Making in Airway Management 41:21 Advice for New Practitioners Thank you to Delta Development Team for in part, sponsoring this podcast. ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠deltadevteam.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ For more content go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠ Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care

Host: Isaretta Riley, MD, MPH Guest: Nicola A. Hanania, MD, MS, FCCP Guest: Jay Peters, MD A recent study assessing the impact of implicit bias on uncontrolled asthma treatment found that a patient's identity and socioeconomic status can unintentionally influence a physician's decision-making, impacting the quality of care. Additionally, a critical gap exists in clinician awareness and implementation of health equity practices, which play a key role in mitigating these unintended consequences. That's why Drs. Isaretta Riley, Nicola Hanania, and Jay Peters come together to explore the latest research on unconscious bias in asthma treatment and provide recommendations for more equitable care. Dr. Riley is an Assistant Professor of Medicine at Duke University School of Medicine in Durham, North Carolina; Dr. Hanania is a Professor of Pulmonary Medicine and the Director of Airways Clinical Research Center at Baylor College of Medicine in Houston, Texas; and Dr. Peters is a Professor Emeritus of Medicine in the Division of Pulmonary Diseases and Critical Care Medicine at the University of Texas, San Antonio. This episode of Deep Breaths: Updates from CHEST was supported by a non-promotional, non-CME educational program brought to you by CHEST in collaboration with and sponsored by GSK.

Artificial Intelligence (AI) is revolutionizing healthcare, and oncology is no exception. In this episode of the Exploring AI in Oncology series, Kristin Maloney, MS, BSN, RN, OCN®, a Certified Oncology Nurse and the Clinical Informatics Lead at Mendel AI, speaks with Dr. Waqas Haque on how AI can address some of the biggest challenges in oncology. She shares more about Mendel's innovative platform, which leverages physician-level cognitive capabilities to enhance data process and improve clinical decision making and patient outcomes. Learn more at: https://oncdata.com/mendel-ai-with-kristin-maloney

In this episode of the 3 Pie Squared - ABA Business Leaders podcast, we sit down with Amanda Ralston, founder of Nonbinary Solutions and creator of Knowetic.AI, to discuss how AI is transforming clinical decision-making in the ABA field. Amanda shares her insights on balancing innovation and ethics, building effective clinical tools, and the importance of quality in ABA services. Learn how Knowetic.AI supports clinicians by providing structured pathways to improve patient outcomes and ensure medical necessity. Whether you're a seasoned practitioner or just starting your journey, Amanda's unique perspective and wealth of experience will inspire and inform your practice. Don't miss this conversation about the intersection of technology, clinical expertise, and patient care. Want to learn more about NonBinary Solutions? Check out Knowetic AI! Knowetic.AI, a clinical decision support system helping clinicians streamline their processes and enhance patient outcomes. Learn more at www.knowetic.ai. Starting a practice or looking to enhance your existing one? Download our free startup list here. Access exclusive resources for ABA business leaders by exploring membership options with 3 Pie Squared here.

In this episode of the PFC Podcast, Dennis and Alex discuss the complexities of trauma surgery, particularly focusing on pelvic injuries and the use of pelvic binders. They explore the subjective nature of truth in medical practice, the importance of research and evidence in trauma care, and the anatomy and physiology related to pelvic injuries. The conversation delves into injury patterns, damage control surgery, and the challenges faced in operational environments. They also engage in a debate about the efficacy of pelvic binders, weighing the evidence and risks involved in their use during trauma care. In this conversation, Dennis discusses the critical importance of evidence-based practice in combat medicine, particularly regarding the use of pelvic binders. He emphasizes the need for medical professionals to understand the nuances of pelvic injuries, especially in a combat environment, and how these injuries differ from civilian cases. The discussion also covers the structured approach to prolonged field care, the management of blood transfusions, and the challenges of imaging in trauma assessment. Dennis advocates for clinical decision-making that prioritizes patient safety and effective care, while also acknowledging the emotional weight of these decisions in high-stakes environments. Takeaways Truth is subjective and varies by perception. Disagreement in medical practice can lead to better patient care. Understanding research quality is crucial in medical decisions. Venous bleeding is more common in pelvic injuries than arterial. Damage control surgery involves multiple phases of patient management. Operational environments present unique challenges for trauma care. Pelvic binders are debated in their effectiveness and necessity. Surgical decision-making requires weighing risks and benefits. Evidence-based medicine is essential but often lacking in operational settings. The role of pelvic binders in trauma care remains contentious. Evidence is crucial in medical practice to avoid misinformation. Dismounted IED blasts result in unique injury patterns. Understanding research and statistics is essential for medical professionals. Pelvic binders may not always be beneficial in every injury case. Timely blood transfusions are critical in managing trauma patients. Imaging plays a vital role in assessing pelvic injuries. Clinical decision-making should be based on patient stability and evidence. Prolonged field care requires a structured approach to patient management. Team collaboration is essential in making difficult medical decisions. Continuous education and training are vital for operational medics. Chapters 00:00 Introduction to the Podcast and Guest 02:58 Understanding Trauma Surgery and Pelvic Injuries 06:13 Research and Evidence in Trauma Care 09:06 Anatomy and Physiology of Pelvic Injuries 12:04 Injury Patterns and Their Implications 14:53 Damage Control Surgery and Patient Management 17:48 Operational Environment Challenges 21:03 The Role of Pelvic Binders in Trauma Care 23:52 Debate on Pelvic Binders and Evidence 26:51 Surgical Decision Making in Trauma 29:47 Conclusion and Final Thoughts 45:19 The Importance of Evidence in Medical Practice 52:34 Understanding Pelvic Injuries in Combat 53:59 Prolonged Field Care: A Structured Approach 01:00:03 Managing Blood Transfusions in Critical Care 01:10:06 The Role of Imaging in Trauma Assessment 01:18:00 Clinical Decision-Making in Prolonged Field Care For more content go to ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠www.prolongedfieldcare.org⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠ Consider supporting us: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/ProlongedFieldCareCollective⁠⁠⁠⁠⁠⁠ or ⁠⁠⁠⁠⁠⁠www.lobocoffeeco.com/product-page/prolonged-field-care

To discover the whole episode type "#44 - Predicting cancer treatment response - Andre Esteva - Artera" on your preferred streaming platform.

Article - The Impact of MRI-Based Advanced Neuroimaging on Neurooncologists'Clinical Decision-Making in Patients With Posttreatment High-GradeGlioma: A Prospective Survey-Based Study Atefeh Zeinoddini, MD, discusses the AJR article by Dagher et al. exploring the impact of advanced neuroimaging on management decisions after treatment for high-grade glioma, based on surveys of neurooncologists.

Dr. Alan Rozanski is Professor of Medicine at the Icahn School of Medicine at Mount Sinai, and Chief Academic Officer, Executive Director of Cardiac Education and Fellowship Training Programs, and Director of Nuclear Cardiology for the Department of Cardiology at Mount Sinai St. Lukes.  A graduate of Yale University and the Tufts University School of Medicine, Dr. Rozanski completed his Internal Medicine and Cardiology Fellowship training at Mount Sinai Hospital and a fellowship in Nuclear Medicine at Cedars-Sinai Medical Center in Los Angeles. While at Cedars-Sinai Medical Center, Dr. Rozanski founded a large multi-disciplinary program in Preventive and Rehabilitative Cardiology and initiated research which helped lead to the creation of a new field of Behavioral Cardiology. This led to a prestigious Sabbatical Fellowship from the MacArthur Foundation to study the determinants of health-promoting and health-damaging behaviors alongside many leading behavioral clinicians across the nation. In 1990, Dr. Rozanski joined the cardiology staff of St. Lukes/Roosevelt Hospital (now Mount Sinai St. Lukes and Mount Sinai West Hospitals) where he eventually served as Chief of Cardiology before assuming his current positions.     Dr. Rozanski is noted for his unique clinical and academic focus and novel research that uniquely integrates the fields of Preventive Cardiology with Health Psychology and Behavioral Medicine.  In addition, Dr. Rozanski is a leading expert in applying Cardiac Imaging for optimal Risk Assessment and Clinical Decision Making among patients who are candidates for cardiac testing due to risk factors or symptoms which are suggesting of heart disease.    Dr. Rozanski is the co-author of over 270 peer-reviewed medical articles, book chapters and medical editorials, many of which are considered seminal contributions to the fields of Cardiology and/or Health Psychology.

Episode Overview: The integration of augmented intelligence (AI) in clinical settings is revolutionizing healthcare, but it also brings its own set of challenges. In this episode, Maria Granzotti, MD, MBA, CPE, CHCQM, FABQAURP, FACHE, dives into the current landscape of clinical augmented intelligence (CAI). She defines CAI, discusses its primary purposes and benefits, and examines its potential to reduce healthcare costs. Key Questions: • How is CAI different from traditional AI? • What does "human in the loop" mean in the context of CAI? • Is now the right time for CAI? Episode Highlights: • Technology Integration: Discover how CAI seamlessly integrates into existing clinical workflows, enhancing the tools physicians already use. • Quality Improvement: Learn from real-world examples about how CAI supports quality and safety initiatives in healthcare. • Healthcare Delivery: Explore how CAI can revolutionize healthcare delivery by reducing administrative burdens and shifting the focus back to patient care. About the Expert: Maria Granzotti, MD, MBA, CPE, CHCQM, FABQAURP, FACHE, is the chief medical advisor and clinical strategist for Digital Strategies Group, LLC. With 15 years of experience in healthcare executive leadership and 20 years in emergency medicine, she has a proven track record of delivering value and prioritizing patient safety. Granzotti has led quality and safety initiatives at a multihospital system in Texas and has played a pivotal role in shaping strategies for over 150 hospitals across the country. The Big Picture: CAI is creating new possibilities for patients and physicians, driving advancements in technology and quality in healthcare. Learn more about the American Association for Physician Leadership.

Ambivalence is a tough concept when it comes to decision-making. On the one hand, when people have ambivalence but haven't explored why they are ambivalent, they are prone to bad, value-incongruent decisions. On the other hand, acknowledging and exploring ambivalence may lead to better, more ethical, and less biased decisions. On today's podcast, Joshua Briscoe, Bryanna Moore, Jennifer Blumenthal-Barby, and Olubukunola Dwyer discuss the challenges of ambivalence and ways to address them. This podcast was initially sparked by Josh's “Note From a Family Meeting” Substack post titled “Ambivalence in Clinical Decision-Making,” which discussed Bryanna's and Jenny's 2022 article titled “Two Minds, One Patient: Clearing up Confusion About Ambivalence." Bryanna's and Jenny's article is particularly unique as it discusses these “ambivalent-related phenomena” and that these different kinds of “ambivalence” may call for different approaches with patients, surrogates (and health care providers): In addition to defining these “ambivalent related phenomena” we ask our guests to cover some of these topics: Is ambivalence good, bad, or just a normal part of decision-making? Does being ambivalent mean you don't care about the decision? What should we be more worried about in decision-making, ambivalence or the lack thereof? The concern about resolving ambivalence too quickly, as it might rush past important work that needs to be done to make a good decision. What about ambivalence on the part of the provider?  How should we think about that? How do you resolve ambivalence? Lastly, the one takeaway point from this podcast is that the next time I see ambiguity (or have it myself), I should ask the following question: “I see you are struggling with this decision. Tell me how you are feeling about it.”  

Hey friends!   Scot Morrison is a physical therapist, strength coach, and educator who currently works in special operations.  Scot has a special interest in clinical decision making and managing uncertainty in clinical practice.  We also cover the importance of understanding what you're actually measuring when you perform objective testing.  Finally, we wrap up the conversation talking about the relationship between constraints and exercise dosage.   Enjoy! CALU FB Community: https://www.facebook.com/groups/calucommunity/

The field of oncology treatments is advancing very fast with innovative therapies and approaches on the market every day. It can get very tricky to support these therapies from an IT perspective, which is what you will hear more about in this discussion. I spoke with Anish Patankar, SVP and GM of Elekta's Oncology Software Solutions, and we discusses: How to go about the US hospital market,  Development in software for oncology treatments, Challenges in scaling healthcare IT software across markets.  Newsletter: https://fodh.substack.com/ www.facesofdigitalhealth.com Show notes: [00:00:00] Introduction to Elekta [00:02:00] Elekta's Global Presence [00:04:00] US Market Focus [00:06:00] Growth in Developing Countries [00:08:00] Segmentation and Technology Adoption in the US [00:10:00] Untapped Needs and Opportunities in the US [00:12:00] Elekta's Use of AI [00:14:00] Patient Feedback and Clinical Decision Making [00:18:00] Navigating Legacy Software in Healthcare IT [00:20:00] Modernization and Customer Satisfaction [00:22:00] Global Standardization and Regulation Challenges [00:24:00] Interoperability and Open Ecosystem [00:26:00] Future of Oncology Market Development: the interplay between medications and radiation, and the potential of theranostics. [00:28:00] Exciting Technologies in Healthcare Beyond Oncology: personalized healthcare, digital twins [00:30:00] Cautions for the Future: The critical debate on the balance between innovation speed and safety, particularly with generative AI.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KBV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 17, 2025.Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).Faculty/PlannerKomal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.Faculty/PlannerProfessor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KBV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 17, 2025.Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).Faculty/PlannerKomal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.Faculty/PlannerProfessor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KBV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 17, 2025.Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).Faculty/PlannerKomal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.Faculty/PlannerProfessor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/KBV865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 17, 2025.Simplifying the Complicated: An Algorithmic Guide for Clinical Decision-Making in HR+, HER2- EBC and MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, Inc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biopharma Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, Inc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer Ingelheim Pharmaceuticals, Inc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serono, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; ImmunoGen, Inc.; Immunomedics, Inc.; Incyte; Infinity Pharmaceuticals, Inc.; InvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, Inc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; MedImmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove Inc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr Immunotherapeutics; Plexxikon; Radius Health, Inc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen Inc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, Inc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; TapImmune Inc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks Inc. (all paid to institution).Faculty/PlannerKomal Jhaveri, MD, FACP, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; AstraZeneca; Blueprint Medicines; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Jounce Therapeutics, Inc.; Lilly/Loxo Oncology; Menarini Group/Stemline Therapeutics; Novartis Pharmaceuticals Corporation; Pfizer; Scorpion Therapeutics; Seattle Genetics, Inc. (Seagen Inc.); Sun Pharma Advanced Research Company; and Taiho Oncology, Inc.Grant/Research Support from ADC Therapeutics SA; AstraZeneca; Blueprint Medicines; Debiopharm; Genentech, Inc.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novita Pharmaceuticals, Inc.; Pfizer; Puma Biotechnology, Inc.; Scorpion Therapeutics; and Zymeworks Inc.Faculty/PlannerProfessor Stephen Johnston, MA, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; Puma Biotechnology, Inc.; and Sanofi.Grant/Research Support from AstraZeneca; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Lilly; Novartis Pharmaceuticals Corporation; Pfizer; and Puma Biotechnology, Inc.Speakers Bureau participant with AstraZeneca; Eisai Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; and Pfizer.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Welcome to Season 5 of the podcast. In this first episode,  It's my great pleasure to introduce Professor Jill Klein. In addition to numerous other hats and talents Jill is Professor  of Marketing at Melbourne Business School and Professorial Fellow in Medical Education at Melbourne Medical School.     Jill received her Ph.D. in Social Psychology from the University of Michigan in 1990 and since then has taught at top universities and business school around the world. She joined the faculty at Kellogg Graduate School of Management, Northwestern University in 1990, and the faculty at INSEAD in 1997.She has also been a visiting scholar at Duke University, Helsinki School of Business and Economics, and University of Texas at Austin. She joined Melbourne Business School in 2009, and Melbourne Medical School in 2015.      Jill teaches Resilience and Well-Being, Managerial Judgment, Clinical Decision Making, and Leadership. Her research interests are in resilience and well-being, decision making, business ethics and ethical consumption. She has published widely, including in the British Medical Journal, Medical Education, Management Science, Journal of Consumer Researchand Harvard Business Review. She authored the book, We Got the Water: Tracing My Family's Path Through Auschwitz, and is currently writing (with Dr. Vinita Rane), Thriving in Medial School, a well-being book for medical students. She often appears in the media, and has had pieces published in The Guardian, Australian Financial Review, The Age and Huffington Post.     I had the great privilege of being taught Managerial Judgement  by Jill at the Melbourne Business School in late 2023 and was struck by  the importance of her work and applied expertise in healthcare. This work is very much aligned with this podcast mission and listenership. In this conversation we hear more about Jill's early career experiences and how these may have contributed to her subsequent trajectory, research interests and teaching mission. I was particularly keen to explore her work around clinical error and growth mindset. Jill fields some tough questions from me on the topic of resilience in healthcare and we are treated to a taster of her upcoming book "Thriving in Medical School".  I anticipate a successful "Thriving In..." book series to come.  Thank you Professor Klein, I very much hope there will be part 2 to this episode at a later date.This episode of dedicated to incredible life and memory of Gene Klein, Jill's dear and    beloved best friend and father.Links/References/ Contacts:https://mbs.edu/faculty-and-research/faculty/jill-kleinhttps://www.amazon.com.au/We-Got-Water-Tracing-Auschwitz/dp/0615806961 Growth mindset YouTube series for medical studentshttps://youtu.be/YdmlTf8zTYQ?si=tpUvLC56C2fXLHeMJill's Recommendations:https://ig.ft.com/sites/business-book-award/books/2023/winner/right-kind-of-wrong-by-amy-edmondson/The Mind Full Medic Podcast is proudly sponsored by the MBA NSW-ACT Find out more about their service or donate today at www.mbansw.org.auDisclaimer: The content in this podcast is not intended to constitute or be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your doctor or other qualified health care professional. Moreover views expressed here are our own and do not necessarily reflect those of our employers or other official organisations.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, downloadable Practice Aids, slides, and complete CME/MOC/NCPD/CPE/AAPA/IPCE information, and to apply for credit, please visit us at PeerView.com/RRR865. CME/MOC/NCPD/CPE/AAPA/IPCE credit will be available until February 9, 2025.Custom Care Compass: Mastering Multifactorial Clinical Decision-Making in High-Risk HR+, HER2- MBC In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by an educational grant from Lilly.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerJoyce O'Shaughnessy, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie Inc.; Agendia; Amgen Inc.; Aptitude Health; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Celgene Corporation; Daiichi Sankyo, Inc.; Duality Biologics; Eisai Inc.; F. Hoffmann-La Roche Ltd.; G1 Therapeutics, Inc.; Genentech, Inc.; Gilead Sciences, Inc.; GRAIL, Inc.; Halozyme, Inc.; Heron Therapeutics, Inc.; Immunomedics, Inc.; Ipsen Biopharmaceuticals, Inc.; Lilly; Merck & Co., Inc.; Myriad Genetics, Inc.; Nektar; Novartis Pharmaceuticals Corporation; Ontada LLC; Pfizer; Pharmacyclics LLC; Pierre Fabre group; prIME Oncology; Puma Biotechnology, Inc.; Samsung Bioepis; Sanofi; Scorpion Therapeutics, Inc.; Seagen Inc.; Stemline Therapeutics, Inc./The Menarini Group; Syndax Pharmaceuticals Inc.; Synthon; Taiho Oncology, Inc.; and Takeda Pharmaceutical Company Limited.Faculty/PlannerSara M. Tolaney, MD, MPH, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for 4D pharma plc; Aadi Bioscience, Inc.; ARC Therapeutics; Artios Pharma; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; BeyondSpring Pharmaceuticals Inc.; Blueprint Medicines; Bristol Myers Squibb; CytomX Therapeutics, Inc.; Daiichi Sankyo Inc.; eFFECTOR Therapeutics; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Incyte; Jazz Pharmaceuticals; Lilly; Merck & Co., Inc.; Myovant Sciences Ltd.; Natera; Novartis Pharmaceuticals Corporation; Pfizer; Reveal Genomics; Sanofi; Seattle Genetics, Inc.; Stemline Therapeutics, Inc./The Menarini Group; Systimmune; Tango Therapeutics; Umoja Biopharma; Zentalis; Zetagen; and Zymeworks Inc.Grant/Research Support from AstraZeneca; Bristol Myers Squibb; Cyclacel Pharmaceuticals, Inc.; Eisai Inc.; Exelixis, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Gilead Sciences, Inc.; Lilly; Merck & Co., Inc.; NanoString Technologies Inc.; Nektar; Novartis Pharmaceuticals Corporation; Pfizer; Sanofi; and Seattle Genetics, Inc.Other Financial or Material Support from Steering committee for CytomX Therapeutics, Inc. and OncXerna Therapeutics, Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

We talk to Prof. Dr. Harald Kittler (MedUni Vienna). Kittler is a dermatologist and teaches and researches in vivo skin imaging, artificial intelligence, machine learning, simulation and computational biology, among other things. We talk about the influence of machine learning and AI in medicine, especially in dermatology. Links: https://www.meduniwien.ac.at/hp/n094-malignantdiseases/research-groupssupervisors/supervisors-h-k/kittler-harald/ https://www.cecog.org/ai-in-medicine-vision-reality-legal-aspects/

CardioNerds co-founder Dr. Amit Goyal, series co-chair Dr. Colin Blumenthal, and episode lead Dr. Anushka Tandon to discuss pharmacologic anticoagulation options in atrial fibrillation with Drs. Ashley Lochman and Chris Domenico. The case-based review helps clarify some key concepts, such as when warfarin is preferred for anticoagulation, who may be a good DOAC (direct-acting oral anticoagulant) candidate, how to choose an appropriate DOAC agent, and how to manage anticoagulation therapy in patients already on antiplatelet therapies. Notes were drafted by Dr. Anushka Tandon. The episode audio was edited by student Dr. Shivani Reddy. This CardioNerds Atrial Fibrillation series is a multi-institutional collaboration made possible by contributions of stellar fellow leads and expert faculty from several programs, led by series co-chairs, Dr. Kelly Arps and Dr. Colin Blumenthal. This episode was planned and recorded prior to the release of the 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation. Please refer to this guideline document for the most updated recommendations. We have collaborated with VCU Health to provide CME. Claim free CME here! CardioNerds Atrial Fibrillation PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls and Quotes - Anticoagulation Pharmacology Avoid potentially fatal errors with this terminology tip for correctly referencing non-warfarin oral anticoagulant agents: it's DOAC (like, please DO use AntiCoagulation), not NOAC (imagine someone interpreting that as “NO AntiCoagulation for this patient” at discharge – yikes)! Sometimes, an oldie really is a goodie – warfarin is recommended over DOACs for patients with mechanical heart valves, moderate-to-severe mitral stenosis, anti-phospholipid antibody syndrome (APLS), left ventricular (LV) thrombus, higher INR goals, or DOAC failure. Patient preference and medication costs should also be considered – at the end of the day, “the best drug is the drug that a patient is willing to take!” Standard-dose rivaroxaban or apixaban may be considered for use in patients weighing >120kg or with BMI >40; use of other DOACs should be limited to pts weighing =/< 120kg or with BMI =/< 40. The pharmacists involved in this podcast promise they don't have stock in apixaban! It just often happens to be the preferred DOAC option in certain scenarios – think patients with severe renal impairment (including ESRD) or with an increased risk for bleeding events (including older adults, those with a history of GI bleed, etc). In general, dual therapy (DOAC or warfarin + P2Y12 inhibitor) is non-inferior to triple therapy (oral anticoagulant + P2Y12 inhibitor + aspirin) at preventing thrombotic events but is associated with a lower risk of bleeding events. Most patients can be transitioned to dual therapy after 7-30 days on triple therapy post-percutaneous coronary intervention. What's that on the horizon? Factor XI inhibitors may become the breakout stars of anticoagulation – multiple investigational agents are being studied for their potential to reduce thrombotic risk without significantly increasing bleeding risk in patients with indications for anticoagulation therapy…at least that's the theorize hope. Watch this space! Notes - Anticoagulation Pharmacology In which cases is warfarin preferred over DOACs in patients with atrial fibrillation? Long-term anticoagulation with warfarin is indicated in patients with atrial fibrillation and either a mechanical valve or moderate-to-severe mitral stenosis (i.e., valvular atrial fibrillation as defined in the 2019 AHA/ACC/HRS guidelines on atrial fibrillation [1]). The REALIGN trial [2] showed increased rates of thromboembolic and bleeding complications with dabigatran vs.

Please visit answersincme.com/VVM860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in oncology discusses the relevance of real-world evidence on the frontline use of CDK4/6 inhibitors in patients with HR+/HER2- metastatic breast cancer. Upon completion of this activity, participants should be better able to: Recognize ways that good quality real-world evidence (RWE) can complement findings from clinical trials in patients with HR+/HER2- metastatic breast cancer (mBC); Outline the clinical relevance of incorporating RWE on the frontline use of CDK4/6 inhibitors into shared decision-making with patients who have HR+/HER2- mBC; and Describe patient-centered strategies to integrate RWE into clinical decision-making discussions with patients who have HR+/HER2- mBC.

The Emergency Department is perhaps the singular environment in a hospital where the greatest concentration of decisions are made with the least amount of clinical data; and the acuity-level assigned at triage can massively impact the trajectory of care for apatient. Additionally, Emergency Departments in the United States have experiencedunprecedented levels of crowding over the last two decades, with correlation to worsened patient outcomes, preventable errors, and staff burnout.In 2017, the ED at Johns Hopkins deployed a CDS tool that leverages AI to generaterisk-driven triage acuity recommendations, instead of relying on resource-based ESI. The tool has provided more reliable detection of patients with critical illness and reduced the time patients wait for care. They've also seen marked decrease in those assigned to the mid-acuity level 3, and instead more utilization of the low-acuity levels 4 and 5, which lends to better fast-track throughput for those patients who are to be discharged.Jeremiah Hinson, MD PhD, will speak of his experience developing and utilizing the toolwith his team at Johns Hopkins.

Health Affairs' Editor-in-Chief Alan Weil interviews Tina Hernandez-Boussard of Stanford University on her recent paper exploring ways that we can promote equity in clinical decision-making and how to dismantle race-based medicine.Order the October 2023 issue of Health Affairs.Currently, more than 70 percent of our content is freely available - and we'd like to keep it that way. With your support, we can continue to keep our digital publication Forefront and podcasts free for everyone.

Featuring perspectives from Dr Prithviraj Bose and Dr Andrew T Kuykendall, moderated by Dr Mascarenhas, including the following topics: Introduction (0:00) Clinical Decision-Making for Patients with Myelofibrosis (MF) — Dr Bose (2:27) Management of MF in Special Patient Populations — Dr Mascarenhas (19:26) Future Directions in the Management of MF — Dr Kuykendall (48:09) CME information and select publications

Clinical decision making tools for ruling in and out the need for medical imaging following foot and ankle injuries.

Dereck Paul, MD is a cofounder and the CEO of Glass Health, an AI-powered medical knowledge management and clinical decision-making platform that helps clinicians provide better patient care. Previously, he was an internal medicine resident at Brigham and Women's Hospital, Harvard Medical School and a medical student at the UCSF School of Medicine. Host: David Wu Twitter: @davidjhwu  Audio Producer + Video Editor + Art: Saurin Kantesaria Instagram: saorange314 Social Media: Nikhil Kapur Time Stamps: 01:13 - From music major to med school to making a startup 06:30 - Poor healthcare technology = physician burnout, the motivation for building Glass Health 09:15 - Glass Notebook - "Notion for doctors" 11:24 - Building a startup in the era of Chat-GPT 13:50 - What doctors need in an AI-assisted diagnosis software 19:15 - Transition towards a more AI oriented technology - Glass AI 23:00 - How does Glass AI make accurate diagnoses? 28:40 - Why doctors need to be involved in building clinical AI products 30:50 - Practical usage of Glass AI in the clinic 33:04 - Why Glass AI will be more trustworthy than Chat-GPT in writing clinical notes 37:43 - Why LLMs don't need to be perfect for use in the clinic 40:28 - Ethical implications of Glass AI and similar products 45:34 - Should we disclose when we use AI to write a clinical note? 49:13 - What do you think the future of AI in medicine will look like in 10-20 years? 52:30 - What brings you joy? What gives your life meaning? 56:10 - Would you ever go back to being a musician?

Listen to our latest podcast, featuring expert guests Domenica Lorusso, Catholic University of Rome, Italy and Nicole Concin, Medical University of Innsbruck, Austria. This episode discusses key findings from recent research into predictive biomarkers in endometrial cancer, specifically focusing on the potential for these biomarkers to inform clinical decision making. This podcast was funded by a medical educational grant from GSK, with the purpose of enhancing the fundamental understanding of oncology specialists of key data and the latest advancements in endometrial cancer care.

For years Advisory Board has been researching how technology and macro-economic forces are shaping clinical decision-making, and recent advances in large language models and AI have the potential to make an impact like we've never seen before. In this episode, guest host and Advisory Board life sciences expert Soloman Banjo invites Advisory Board expert Amanda Okaka and Optum's Senior Vice President of Clinical Innovation Dr. Kevin Larson to discuss the technologies that will change clinical decision-making in the next decade, its implications, and what organizations should be thinking about as they integrate them into clinical workflows. Links: How clinicians will use evidence in 2032 5 takeaways from our expert panel on technology's role in the future of clinical decision-making The future of clinical decision-making at the institutional level Learn more about Advisory Board's upcoming webinar on key innovations in cancer care for patients by visiting https://www.advisory.com/resources/events

In episode 72 of The Gradient Podcast, Daniel Bashir speaks to Brigham Hyde.Brigham is Co-Founder and CEO of Atropos Health. Prior to Atropos, he served as President of Data and Analytics at Eversana, a life sciences commercialization service provider. He led the investment in Concert AI in the oncology real-world data space at Symphony AI. Brigham has also held research faculty positions at Tufts University and the MIT Media Lab.Have suggestions for future podcast guests (or other feedback)? Let us know here or reach us at editor@thegradient.pubSubscribe to The Gradient Podcast:  Apple Podcasts  | Spotify | Pocket Casts | RSSFollow The Gradient on TwitterOutline:* (00:00) Intro* (01:55) Brigham's background* (06:00) Current challenges in healthcare* (12:33) Interpretablity and delivering positive patient outcomes* (17:10) How Atropos surfaces relevant data for patient interventions, on personalized observational research studies* (22:10) Quality and quantity of data for patient interventions* (27:25) Challenges and opportunities for generative AI in healthcare* (35:17) Database augmentation for generative models* (36:25) Future work for Atropos* (39:15) Future directions for AI + healthcare* (40:56) OutroLinks:* Atropos Health homepage* Brigham's Twitter and LinkedIn Get full access to The Gradient at thegradientpub.substack.com/subscribe

Dr. Doug Maxeiner is a chiropractor, entrepreneur, and software engineer. Throughout his career he has looked for ways to create world class patient care and communication which has led him to the development of ExamXoom.

Learn the ultimate clinical skill of making sound decisions and how to improve your judgments and reasoning in healthcare practice in this intriguing podcast episode on metacognitive awareness and regulation. In this episode of the Healthcare Education Transformation Podcast, we explore the topic of metacognition and how it relates to clinical practice. Our guest, Dr. Ken Kosior shares his insights on metacognition and how it can be taught to health professionals. We begin by discussing what metacognition is and why it is important to make our thinking overt. We then delve into how this applies to clinical decision-making and the pitfalls, biases, and errors that can occur. Dr. Ken Kosior shares his experience in applying cognitive psychology to physical therapy education and how it can be used to teach reasoning-based skills. Tune in to gain valuable insights on how to become a better health professional by developing your metacognitive skills. Dr. Kosior is currently Chair and Assistant Professor in the Department of Physical Therapy. A Quinnipiac Alumni '03, '06, Dr. Kosior has been a full-time faculty member within the School of Health Sciences since 2011. Dr. Kosior's research interests include exploring the intersection of cognitive psychology and health profession education in relation to clinical decision making and student learning. As a SOTL researcher Dr. Kosior looks to enhance the educational experience of health profession students through teaching metacognition and learning strategies. Reach out to Dr. Kosior via email at ken.kosior@qu.edu Dr F Scott Feil is a husband, a father, a physical therapist, a professor, and most recently an Amazon best-selling author. F Scott is also a business coach and mentor despite starting his journey as an English major before landing as a Physical Therapist. He is one of the creators and co-hosts of the Healthcare Education Transformation Podcast which aims to break down the silos between healthcare professions in an attempt to find best practices in teaching and learning throughout healthcare academia. Special thanks to both our sponsors, The NPTE Final Frontier, and Varela Financial! If you are taking the NPTE or are teaching those about to take the NPTE, visit the NPTE FInal Frontier at www.NPTEFF.com and use code "HET" for 10% off all purchases at the website...and BREAKING NEWS!!!! They now have an OCS review option as well... You're welcome! You can also reach out to them on Instagram @npteff If you're a PT and you have student loan debt, you gotta talk to these guys. What makes them unique is that they view financial planning as like running hurdles on a track. And for PTs, the first hurdle many of us run into is student loan debt. Varela Financial will help you get over that hurdle. They not only take the time to explain to you which plans you individually qualify for and how those plans work, but they ALSO take the time to show you what YOUR individual case looks like mapped out within each option. So if you're looking for help on your student loan debt, or any area of your personal finances, we highly recommend working with them. You can check out Varela Financial out at varelafinancial.com. Feel free to reach out to us at:  http://healthcareeducationtransformationpodcast.com/ https://www.facebook.com/HETPodcast https://twitter.com/HETpodcast Instagram: @hetpodcast @dawnbrown_pt @pteducator @dawnmagnusson31 @farleyschweighart @mail.in.stew.art @ujima_institute For more information on how we can optimize and standardize healthcare education and delivery, subscribe to the Healthcare Education Transformation Podcast on Apple Podcasts or wherever you listen to podcasts.

Our guest today is Dr. Richard Loria, physician consultant with EBSCO. Dr. Loria is one of the presenters from our recent webinar, “Using a Point-of-Care Clinical Decision Support Platform to Drive Practice Success,” and he is here to share with our listeners the ways that DynaMed can help clinicians make more efficient, accurate decisions. Resources: • Learn more about DynaMedex www.ebsco.com/dynamedex • Listen to Dr Loria's deep dive webinar on how DynaMedex can drive group practice success in the MGMA webinar brought to you by EBSCO. https://mgma.com/practice-resources/products/using-a-point-of-care-clinical-decision-support-pl Sponsors: MGMA Events: This episode is brought to you by the Medical Practice Excellence: Financial and Operations Conference 2023. During our premiere spring event, attendees will gain key insights from both disciplines and learn about topics that shape the future success of medical practice organizations. Go to mgma.com/mpe23 to learn more and to register today. DynaMedex: Empowering healthcare professionals with advanced evidence-based clinical decision support to help improve patient outcomes. Learn more at DynaMedex.com. Humana: The latest Value-Based Care Report from Humana outlines many interesting findings and highlights how some physician practices found creative paths to success. Check it out now at Humana.com/VBC. Humana is working closely with physician practices on their value-based journeys. If you would like additional tools and resources related to medical practice leadership email us at podcasts@mgma.com.

Have you ever been in a situation where a physician orders a drug and when you ask, “How much will that cost?,” the response you received was, “I don't know, you'll have to call your health plan.” Or you are surprised at the pharmacy when you pick up your prescription and the cost is really high and you ask for an alternative and then deal with that hassle. Arrive Health is changing all that. They are providing real-time, drug pricing data to the physician in the office, at the time the script is being written. With us today is Kyle Kiser the CEO of Arrive Health. Kyle is going to share what Arrive Health is doing to get cost information to the point of care so the physician and patient can make the best decision. Show notes: Favorite Books: The Four Agreements: A Practical Guide to Personal Freedom by Don Migul Ruiz; Radical Candor: Be a Kick-ass Boss Without Losing your Humanity by Kim Scott